AstraZeneca PLC (AZN) Stock Analysis
AstraZeneca PLC (AZN) is a multinational biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across oncology, cardiovascular, respiratory, and immunology segments. Investors research AZN for its diversified drug portfolio, strong pipeline, and exposure to high-growth therapeutic areas including cancer immunotherapy and rare diseases.
Get a full AI research report on AZN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does AstraZeneca PLC do?
AstraZeneca generates revenue by developing and selling branded prescription medications to hospitals, pharmacies, and healthcare systems globally. The company operates across six main therapeutic areas: oncology (including Tagrisso, Imfinzi, and Enhertu), cardiovascular (Brilinta, Farxiga), respiratory and immunology (Symbicort, Fasenra, Tezspire), renal and metabolism (Farxiga, Lokelma), vaccines and immune (Beyfortus, Evusheld), and specialty care (Soliris, Ultomiris). Revenue is driven by both established medicines and newer launches, with profitability supported by a gross margin of 81.5% and operating margin of 27.9%.
Bull case
- ✓Strong gross margin of 81.5% and operating margin of 27.9% demonstrate efficient cost structure and pricing power in key markets.
- ✓Forward P/E of 16.6x is materially lower than trailing P/E of 28.7x, suggesting market expectations for earnings growth as newer drugs mature and pipeline candidates advance.
- ✓Diversified portfolio across six therapeutic areas reduces dependence on any single drug and provides multiple revenue streams in high-demand segments like oncology and respiratory immunology.
- ✓Return on equity of 23.5% indicates efficient capital deployment and strong profitability relative to shareholder capital.
- ✓PEG ratio of 1.39 suggests valuation is not stretched relative to expected earnings growth rate.
Bear case
- ✗Current ratio of 0.909 and quick ratio of 0.701 indicate potential near-term liquidity constraints, with current liabilities exceeding current assets.
- ✗Debt-to-equity ratio of 71.8% reflects a highly leveraged capital structure, which increases financial risk and limits flexibility for acquisitions or shareholder returns.
- ✗Trailing P/E of 28.7x is elevated, reflecting high market expectations that must be met by pipeline success and revenue growth to justify current valuation.
- ✗Pharmaceutical companies face ongoing patent expiration risks on key drugs, generic competition, and regulatory pricing pressures in major markets.
- ✗Dividend yield of 1.62% is modest, and payout ratio of 47.7% leaves limited room for dividend growth without earnings expansion.
AZN valuation & financial health
AstraZeneca trades at a trailing P/E of 28.7x but a forward P/E of 16.6x, indicating the market is pricing in meaningful earnings growth ahead. The company's profitability metrics are strong—net margin of 17.2%, ROE of 23.5%, and ROA of 8.5%—reflecting operational efficiency and effective asset use. However, the balance sheet shows leverage concerns: a debt-to-equity ratio of 71.8% and a current ratio below 1.0 suggest reliance on debt financing and potential liquidity tightness. The PEG ratio of 1.39 implies valuation is reasonable relative to growth expectations, but investors should monitor whether pipeline advances and new product launches deliver the earnings growth the forward multiple assumes.
The bottom line
AstraZeneca presents a tension between operational strength and balance-sheet risk. The company's high margins, diversified portfolio, and forward earnings growth expectations support a lower forward multiple, but the elevated trailing P/E, high leverage, and weak current ratio warrant scrutiny. Key factors to weigh include the clinical and commercial success of pipeline candidates, patent cliff timing on major drugs, and management's capital allocation priorities. Investors should monitor quarterly earnings, pipeline progress, and debt reduction efforts to assess whether the company can sustain growth and improve financial flexibility.
Frequently asked questions
What does AstraZeneca PLC do?
AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines across oncology, cardiovascular, respiratory, immunology, vaccines, and specialty care. The company operates globally and generates revenue by licensing and selling branded drugs to healthcare systems and pharmacies.
Is AZN overvalued or undervalued?
AZN's trailing P/E of 28.7x is elevated, but the forward P/E of 16.6x and PEG ratio of 1.39 suggest the market is pricing in significant earnings growth. Valuation fairness depends on whether the company delivers on pipeline milestones and new product launches; investors should compare these multiples to peers and growth expectations.
What are AstraZeneca's main revenue drivers?
Key revenue drivers include oncology drugs (Tagrisso, Imfinzi, Enhertu), cardiovascular medicines (Brilinta, Farxiga), respiratory therapies (Symbicort, Fasenra, Tezspire), and specialty immunology products (Soliris, Ultomiris). Revenue growth depends on market adoption of newer launches and pipeline candidates reaching commercialization.
Is AZN financially healthy?
AstraZeneca shows strong profitability (27.9% operating margin, 23.5% ROE) but has balance-sheet concerns: a current ratio of 0.909 and debt-to-equity of 71.8% indicate leverage and potential liquidity tightness. The company is profitable but relies heavily on debt financing.
What risks should I consider with AZN stock?
Key risks include patent expirations on major drugs, generic competition, regulatory pricing pressures, high financial leverage, weak current liquidity ratios, and dependence on pipeline success. Investors should also monitor clinical trial outcomes and market adoption of new products.
Does AstraZeneca pay a dividend?
Yes, AstraZeneca pays a dividend with a yield of 1.62% and a payout ratio of 47.7%, leaving room for growth if earnings expand. The modest yield reflects the company's focus on reinvestment and debt management.
Research AZN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.